阅读说明：本技术 用于肝细胞癌(hcc)和其他癌症免疫治疗的新型肽和肽组合物 (Novel peptides and peptide compositions for immunotherapy of hepatocellular carcinoma (HCC) and other cancers ) 是由 托尼·温斯切尼克 安德烈·马尔 延斯·弗里切 菲利普斯·穆勒 安妮塔·维贝 萨拉·库彻尔 于 2015-12-16 设计创作，主要内容包括：本发明涉及用于免疫治疗方法的肽、蛋白质、核酸和细胞。特别是,本发明涉及癌症的免疫疗法。本发明进一步涉及单独使用或与其他肿瘤相关肽(刺激抗肿瘤免疫反应或体外刺激T细胞和转入患者的疫苗复合体的活性药物成分)联合使用的肿瘤相关T细胞(CTL)肽表位。与主要组织兼容性复合体(MHC)分子结合的肽或与此同类的肽也可能是抗体、可溶性T细胞受体和其他结合分子的靶标。特别是,本发明涉及数种新型肽序列及其变体,它们源自人肿瘤细胞的HLA-I类和HLA-II类分子,可用于引发抗肿瘤免疫反应的疫苗组合物中或作为开发药物/免疫活性化合物和细胞的目标。(The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the invention relates to immunotherapy of cancer. The invention further relates to tumor-associated T Cell (CTL) peptide epitopes, used alone or in combination with other tumor-associated peptides that stimulate an anti-tumor immune response or stimulate T cells in vitro and the active pharmaceutical ingredient of the vaccine complex transferred into the patient. Peptides that bind to or are cognate to Major Histocompatibility Complex (MHC) molecules may also be targets for antibodies, soluble T cell receptors, and other binding molecules. In particular, the present invention relates to several novel peptide sequences and variants thereof, derived from HLA class I and HLA class II molecules of human tumor cells, useful in vaccine compositions for eliciting anti-tumor immune responses or as targets for the development of pharmaceutical/immunologically active compounds and cells.)